{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:25:28Z","timestamp":1761845128235,"version":"3.37.3"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T00:00:00Z","timestamp":1581033600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T00:00:00Z","timestamp":1581033600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005805","name":"Hyogo Prefecture Health Promotion Association","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100005805","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Introduction<\/jats:title>\n<jats:p>Bevacizumab and gemcitabine are key drugs for treating recurrent epithelial ovarian cancer. However, information about the combination of bevacizumab and gemcitabine is insufficient. We conducted a phase II study to assess the feasibility, clinical activity, and toxicity of this combination chemotherapy.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>This study included women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer who received one to three regimens of platinum-based chemotherapy between April 1, 2015 and December 31, 2018. The patients received bevacizumab 15\u2009mg\/kg intravenously on day 1 and gemcitabine 1000\u2009mg\/m<jats:sup>2<\/jats:sup> intravenously on days 1 and 8 every 21\u2009days until disease progression or unacceptable toxicity. The primary endpoint was the completion rate of three cycles of chemotherapy. This study was registered in the University Medical Information Network (UMIN) Clinical Trials Registry (UMIN000016619).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Among the 19 patients, 18 (95%) received \u22653 and 9 (47%) received \u22656\u2009cycles of the study therapy. The objective response rate was 42% (complete response of 16% and partial response of 26%), and the clinical control rate was 84%. Hematological toxicity included neutropenia grade 3\/4 in 9 patients (47%), anemia grade 3\/4 in 2 (11%), and thrombocytopenia grade 3\/4 in 1 (5%). One patient (5%) had grade 3 hypertension, and 1 (5%) had grade 3 protein urea. Possibly related grade 3 pulmonary toxicity was observed in 1 patient. Three patients needed dose reduction of gemcitabine to 800\u2009mg\/m<jats:sup>2<\/jats:sup> due to treatment delay by 15 to 21\u2009days on day1. There was no treatment delay more than 14\u2009days on day 8. The median progression-free survival duration was 5.1\u2009months and median overall survival duration was 21.3\u2009months.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>The combination chemotherapy with gemcitabine and bevacizumab was feasible, effective and safe. This combination chemotherapy may be explored in a further randomized trial.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13048-020-0617-y","type":"journal-article","created":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T00:06:38Z","timestamp":1581033998000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4031-8091","authenticated-orcid":false,"given":"Shoji","family":"Nagao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai","family":"Kogiku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Shibutani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kasumi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoatsu","family":"Jimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miho","family":"Kitai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaya","family":"Shiozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuko","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,7]]},"reference":[{"key":"617_CR1","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","volume":"32","author":"E Pujade-Lauraine","year":"2014","unstructured":"Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32:1302\u20138.","journal-title":"J Clin Oncol"},{"key":"617_CR2","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1200\/JCO.2007.13.6606","volume":"16","author":"G Ferreadina","year":"2008","unstructured":"Ferreadina G, Ludovisi M, Lorusso D, et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol. 2008;16:890\u20136.","journal-title":"J Clin Oncol"},{"key":"617_CR3","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","volume":"25","author":"DG Mutch","year":"2007","unstructured":"Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2007;25:2811\u20138.","journal-title":"J Clin Oncol"},{"key":"617_CR4","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00280-018-3552-5","volume":"81","author":"K Takasaki","year":"2018","unstructured":"Takasaki K, Miyamoto M, Takano M, et al. Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer: a retrospective analysis. Cancer Chemother Pharmacol. 2018;81:809\u201314.","journal-title":"Cancer Chemother Pharmacol"},{"key":"617_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","volume":"14","author":"J Bennouna","year":"2013","unstructured":"Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013;14:29\u201337.","journal-title":"Lancet Oncol"},{"key":"617_CR6","doi-asserted-by":"publisher","first-page":"5326","DOI":"10.1200\/JCO.2008.16.3212","volume":"26","author":"A Grothey","year":"2008","unstructured":"Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational cohort study (BRiTE). J Clin Oncol. 2008;26:5326\u201334.","journal-title":"J Clin Oncol"},{"key":"617_CR7","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/S1470-2045(14)70439-5","volume":"15","author":"G von Minckwitz","year":"2014","unstructured":"von Minckwitz G, Puglisi F, Cortes J, et al. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:1269\u201378.","journal-title":"Lancet Oncol"},{"key":"617_CR8","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1186\/s12885-018-4505-4","volume":"18","author":"T Shoji","year":"2018","unstructured":"Shoji T, Komiyama S, Kigawa J, et al. An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese gynecologic oncology group study JGOG3023. BMC Cancer. 2018;18:771.","journal-title":"BMC Cancer"},{"key":"617_CR9","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1111\/jog.13664","volume":"44","author":"S Komiyama","year":"2018","unstructured":"Komiyama S, Kugimiya T, Takeya C, et al. Platinum-resistant recurrent ovarian cancer with long survival on bevacizumab and gemcitabine. J Obstet Gyneacol Res. 2018;44:1330\u20134.","journal-title":"J Obstet Gyneacol Res"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-020-0617-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13048-020-0617-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-020-0617-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T05:31:26Z","timestamp":1612762286000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-020-0617-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,7]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["617"],"URL":"https:\/\/doi.org\/10.1186\/s13048-020-0617-y","relation":{},"ISSN":["1757-2215"],"issn-type":[{"type":"electronic","value":"1757-2215"}],"subject":[],"published":{"date-parts":[[2020,2,7]]},"assertion":[{"value":"26 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the local ethics committee of Hyogo Cancer Center before the initiation of patient recruitment, and the study was conducted in accordance with the ethical principles described in the Declaration of Helsinki. All patients provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All the authors have no competing interest directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14"}}